<?xml version="1.0" encoding="UTF-8"?>
<ref id="pmed.1002882.ref061">
 <label>61</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Boeree</surname>
   <given-names>MJ</given-names>
  </name>, 
  <name>
   <surname>Heinrich</surname>
   <given-names>N</given-names>
  </name>, 
  <name>
   <surname>Aarnoutse</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Diacon</surname>
   <given-names>AH</given-names>
  </name>, 
  <name>
   <surname>Dawson</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Rehal</surname>
   <given-names>S</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial</article-title>. 
  <source>Lancet Infect Dis</source>. 
  <year>2017</year>;
  <volume>17</volume>(
  <issue>1</issue>):
  <fpage>39</fpage>â€“
  <lpage>49</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30274-2</pub-id>
  <?supplied-pmid 28100438?>
  <pub-id pub-id-type="pmid">28100438</pub-id>
 </mixed-citation>
</ref>
